title: Expression of Lewis y antigen and integrin αv, β3 in ovarian cancer and their relationship with chemotherapeutic drug resistance.
abstract: OBJECTIVE
  This study investigates the expression of Lewis y antigen, integrin αv, β3 in epithelial ovarian cancer tissues. We further evaluate the relationship between their expression and chemotherapy resistance of ovarian cancer and its possible clinical significance.
  
  
  METHODS
  Tissues of 92 patients with ovarian cancer meeting the inclusion criteria with complete follow-up data were enrolled and divided into chemotherapy resistant group and sensitive group. The expression and relationship of Lewis y antigen and integrin αv, β3 are assessed in paraffin sections using immunohistochemistry and double-labeling immunofluorescence method. Multivariate logistic regression analysis was used to investigate the relationship between age, clinical stage, differentiation, histologic subtype, Lewis y antigen and integrin αv, β3 expression in ovarian cancer patients.
  
  
  RESULTS
  The expression rates of Lewis y antigen and integrin αv in the resistant group, significantly higher than the rates found in the sensitive group (p <0.05). Multivariate analysis showed that the expression of Lewis y antigen, integrin αv and ovarian cancer's clinical stage were independent, drug resistance-related risk factors. The expression levels of Lewis y antigen and integrin αv, β3 were positively correlated with each other.
  
  
  CONCLUSIONS
  A close correlation between Lewis y antigen, integrin αv, β3 and ovarian cancer was observed. Lewis y antigen can influence the biological behavior of a tumor cell as an important composition of integrin αv, β3 by some signal pathway. And the expression of Lewis y antigen, integrin αv and ovarian cancer's clinical stage are both independent, drug resistance-related risk factors.
authors.affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110004, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Gao
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Hu
authors.forename: Dawo
authors.initials: D
authors.lastname: Liu
authors.forename: Juanjuan
authors.initials: J
authors.lastname: Liu
authors.forename: Chuan
authors.initials: C
authors.lastname: Liu
authors.forename: Rui
authors.initials: R
authors.lastname: Hou
authors.forename: Song
authors.initials: S
authors.lastname: Gao
authors.forename: Danye
authors.initials: D
authors.lastname: Zhang
authors.forename: Shulan
authors.initials: S
authors.lastname: Zhang
authors.forename: Bei
authors.initials: B
authors.lastname: Lin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D039564:Integrin alphaV / Q000235:genetics / Q000378:metabolism*; D039661:Integrin beta3 / Q000235:genetics / Q000378:metabolism; D007983:Lewis Blood Group Antigens / Q000235:genetics / Q000378:metabolism*; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D039564:Integrin alphaV; D039661:Integrin beta3; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen